Search results for "Stroma"

showing 10 items of 444 documents

Morphological Evidence of Telocytes in Skeletal Muscle Interstitium of Exercised and Sedentary Rodents

2021

Skeletal muscle atrophy, resulting from states of hypokinesis or immobilization, leads to morphological, metabolic, and functional changes within the muscle tissue, a large variety of which are supported by the stromal cells populating the interstitium. Telocytes represent a recently discovered population of stromal cells, which has been increasingly identified in several human organs and appears to participate in sustaining cross-talk, promoting regenerative mechanisms and supporting differentiation of local stem cell niche. The aim of this morphologic study was to investigate the presence of Telocytes in the tibialis anterior muscle of healthy rats undergoing an endurance training protoco…

0301 basic medicineMuscle tissuePathologymedicine.medical_specialtyStromal cellQH301-705.5PopulationMedicine (miscellaneous)telocytesGeneral Biochemistry Genetics and Molecular BiologyArticleCD117CD117; CD34; Exercise; Sedentary behavior; Skeletal muscle; Stem cell niche; Telocytes; Vimentin03 medical and health sciences0302 clinical medicinevimentinTibialis anterior muscleEndurance trainingsedentary behaviorMedicinestem cell nicheBiology (General)skeletal muscleeducationeducation.field_of_studyexercisebusiness.industrySkeletal musclemedicine.diseaseMuscle atrophy030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisSarcopeniaCD34medicine.symptombusinessBiomedicines
researchProduct

Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the …

2021

In previous studies on localized GISTs, KIT exon 11 deletions and mutations involving codons 557/558 showed an adverse prognostic influence on recurrence-free survival. In the metastatic setting, there are limited data on how mutation type and codon location might contribute to progression-free survival (PFS) variability to first-line imatinib treatment. We analyzed the type and gene location of KIT and PDGFRA mutations for 206 patients from a GIST System database prospectively collected at an Italian reference center between January 2005 and September 2020. By describing the mutational landscape, we focused on clinicopathological characteristics according to the critical mutations and inve…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyStromal cellPDGFRAlcsh:RC254-28203 medical and health sciencesExon0302 clinical medicinePredictive biomarkersInternal medicineGene duplicationmedicineGastrointestinal stromal tumorsProgression-free survivalGeneneoplasmsGiSTbusiness.industryImatinibKITlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisImatinibbusinessMutationsmedicine.drugGIST
researchProduct

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

2018

Abstract Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression …

0301 basic medicineOncologyMalePathologyHematologic MalignanciesBiopsyDatasets as TopicPredictive Value of TestDeconvolutionCohort StudiesTranscriptomeAntibodies Monoclonal Murine-Derived0302 clinical medicineprognosticatorsimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentCluster Analysisdigital expression analysisRandomized Controlled Trials as TopicParaffin EmbeddingHematology; OncologyHematologyMiddle AgedPrognosisCorrigendaProgression-Free SurvivalAlgorithmOncology030220 oncology & carcinogenesisCell-of-originFemaleLymphoma Large B-Cell DiffuseSurvival AnalysiAlgorithmsHumanAdultmedicine.medical_specialtyStromal cellMicroenvironmentFormalin fixed paraffin embeddedPrognosiReproducibility of ResultDissection (medical)03 medical and health sciencesDigital expression analysiYoung AdultPrognosticatorPredictive Value of TestsFormaldehydeInternal medicinemedicineHumansProgression-free survivalGeneSurvival analysisAgedTumor microenvironmentCluster AnalysiProportional hazards modelbusiness.industryGene Expression ProfilingReproducibility of ResultsComputational BiologyOriginal Articlesmedicine.diseaseSurvival AnalysisGene expression profiling030104 developmental biologyDLBCLCohort StudieTranscriptomebusinessDiffuse large B-cell lymphomaDLBCL microenvironment deconvolution cell-of-origin digital expression analysis prognosticators
researchProduct

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

2017

Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…

0301 basic medicineOncologymedicine.medical_specialtyScheduleStromal cellSettore MED/06 - Oncologia Medicalcsh:RC254-282PersonalizationNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicinetyrosine kinase inhibitorQuality of lifeInternal medicineRegorafenibtyrosine kinase inhibitorsmedicineOriginal Researchreferral centresGiSTbusiness.industryGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitors; OncologyGastrointestinal stromal tumourslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspersonalized treatmentClinical PracticeGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitorsreferral centre030104 developmental biologychemistryquality of lifeOncology030220 oncology & carcinogenesisregorafenibbusinessGIST personalized treatment quality of life referral centres regorafenib tyrosine kinase inhibitorsGIST
researchProduct

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

2018

Background: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated with imatinib resumption after progression to conventional TKIs. Methods: A total of 104 eligible advanced GIST patients, previously treated with imatinib, sunitinib and regorafenib, were collected from six referral Italian institutions. Mutational analysis was recorded and correlated with survival and response according to RECIST 1.1 or CHOI criteria. Results: Overall, 71 patients treated with ima…

0301 basic medicineOncologymedicine.medical_specialtyStromal cellrechallengelcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibhemic and lymphatic diseasesmedicineIn patientStromal tumorneoplasmsOriginal ResearchGiSTbusiness.industrySunitinibImatiniblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensexon 11 KIT mutationTKI030104 developmental biologyOncologychemistryexon 11 KIT mutation; GIST; imatinib; rechallenge; TKIimatinib030220 oncology & carcinogenesisbusinessGIST; TKI; exon 11 KIT mutation; imatinib; rechallengemedicine.drugGIST
researchProduct

Long-Term in vivo Evaluation of Orthotypical and Heterotypical Bioengineered Human Corneas.

2020

Purpose: Human cornea substitutes generated by tissue engineering currently require limbal stem cells for the generation of orthotypical epithelial cell cultures. We recently reported that bioengineered corneas can be fabricated in vitro from a heterotypical source obtained from Wharton’s jelly in the human umbilical cord (HWJSC). Methods: Here, we generated a partial thickness cornea model based on plastic compression nanostructured fibrin-agarose biomaterials with cornea epithelial cells on top, as an orthotypical model (HOC), or with HWJSC, as a heterotypical model (HHC), and determined their potential in vivo usefulness by implantation in an animal model. Results: No major side effects …

0301 basic medicinePathology02 engineering and technology:Chemicals and Drugs::Carbohydrates::Polysaccharides::Sepharose [Medical Subject Headings]Umbilical cord:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]heterotypical human corneaTissue engineering:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Lagomorpha::Rabbits [Medical Subject Headings]Cornea:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Optical Imaging::Tomography Optical::Tomography Optical Coherence [Medical Subject Headings]:Organisms::Eukaryota::Animals [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Manufactured Materials::Biomedical and Dental Materials::Biocompatible Materials [Medical Subject Headings]Slit lamp021001 nanoscience & nanotechnologymedicine.anatomical_structure:Anatomy::Sense Organs::Eye::Anterior Eye Segment::Cornea [Medical Subject Headings]tissue engineeringStem cell0210 nano-technologyBiotechnology:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Fibrin [Medical Subject Headings]medicine.medical_specialtyHistologyStromal celllcsh:BiotechnologyBiomedical EngineeringCélulas madre mesenquimatosasBioengineering:Anatomy::Embryonic Structures::Fetus::Umbilical Cord [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models Animal [Medical Subject Headings]03 medical and health sciencesIn vivolcsh:TP248.13-248.65medicine:Anatomy::Cells::Connective Tissue Cells::Stromal Cells::Mesenchymal Stromal Cells [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Engineering::Bioengineering::Cell Engineering::Tissue Engineering [Medical Subject Headings]Wharton’s jelly stem cellsbioengineered corneabusiness.industryTissue engineringeye diseasesEpitheliumCórnea:Anatomy::Cells::Epithelial Cells [Medical Subject Headings]:Anatomy::Tissues::Connective Tissue::Wharton Jelly [Medical Subject Headings]030104 developmental biologyIngeniería de tejidossense organsbusinessartificial cornea
researchProduct

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

2016

AbstractTreatment of high-risk childhood neuroblastoma is a clinical challenge which has been hampered by a lack of reliable neuroblastoma mouse models for preclinical drug testing. We have previously established invasive and metastasising patient-derived orthotopic xenografts (PDXs) from high-risk neuroblastomas that retained the genotypes and phenotypes of patient tumours. Given the important role of the tumour microenvironment in tumour progression, metastasis, and treatment responses, here we analysed the tumour microenvironment of five neuroblastoma PDXs in detail. The PDXs resembled their parent tumours and retained important stromal hallmarks of aggressive lesions including rich bloo…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchStromal cellGenotypeTumour stromaBiologyPolymorphism Single NucleotideMetastasisMetastasisPaediatric cancer03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomamedicineTumor MicroenvironmentAnimalsHumansPatient-derived xenograft (PDX)Tumor microenvironmentTumour microenvironmentNeovascularization Pathologicmedicine.diseaseXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologyLymphatic systemOncology030220 oncology & carcinogenesisCancer-Associated FibroblastsImmunohistochemistryBlood VesselsChildhood NeuroblastomaCancer letters
researchProduct

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients

2016

International audience; Tumor-infiltrating T and B lymphocytes could have the potential to affect cancer prognosis. The objective of this study was to investigate the prognostic significance of tumor infiltration by CD8 and CD4 T cells, and B lymphocytes in patients with localized gastric cancer. In a retrospective cohort of 82 patients with localized gastric cancer and treated by surgery we quantitatively assessed by immunohistochemistry on surgical specimen, immune infiltrates of IL-17(+), CD8(+), Foxp3(+), Tbet(+) T cells and CD20(+) B cells both in the tumor core and at the invasive margin via immunohistochemical analyses of surgical specimens. We observed that CD8(+) and IL17(+) T-cell…

0301 basic medicinePathologymedicine.medical_specialtyStromal cellImmune contextureImmunologyB-cellsOvarian-cancer[SDV.CAN]Life Sciences [q-bio]/CancerExpressionFavorable prognosisT-bet[ SDV.CAN ] Life Sciences [q-bio]/Cancerhistology03 medical and health sciencesLong-term survival0302 clinical medicineImmune systemhuman tumorsmedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyLymphocytesB cellOriginal ResearchCD20B cellsbiologybusiness.industrygastric cancerCarcinomaFOXP3medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyprognosisbusinessOvarian cancerTertiary lymphoid structuresInfiltration (medical)Lung-cancerCD8
researchProduct

Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis

2017

Lymph nodes (LNs) are strategically situated throughout the body at junctures of the blood vascular and lymphatic systems to direct immune responses against antigens draining from peripheral tissues. The current paradigm describes LN development as a programmed process that is governed through the interaction between mesenchymal lymphoid tissue organizer (LTo) cells and hematopoietic lymphoid tissue inducer (LTi) cells. Using cell-type-specific ablation of key molecules involved in lymphoid organogenesis, we found that initiation of LN development is dependent on LTi-cell-mediated activation of lymphatic endothelial cells (LECs) and that engagement of mesenchymal stromal cells is a succeedi…

0301 basic medicinePathologymedicine.medical_specialtygovernment.form_of_governmentOrganogenesis[SDV]Life Sciences [q-bio]Immunology610 Medicine & healthMice TransgenicBiologyChoristoma10263 Institute of Experimental Immunology03 medical and health sciencesMiceImmune systemLymphotoxin beta ReceptormedicineLymph node stromal cellImmunology and AllergyAnimalsLymph nodeCells CulturedComputingMilieux_MISCELLANEOUS2403 ImmunologyReceptor Activator of Nuclear Factor-kappa BMesenchymal stem cellNF-kappa BEndothelial CellsCell DifferentiationMesenchymal Stem Cells2725 Infectious DiseasesEmbryo MammalianCell biologyMice Inbred C57BLHaematopoiesisLymphatic EndotheliumReceptors Lysosphingolipid030104 developmental biologyInfectious Diseasesmedicine.anatomical_structureLymphatic system2723 Immunology and Allergygovernment570 Life sciences; biology[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphLymph NodesSignal Transduction
researchProduct

The Immunomodulatory Properties of the Human Amnion-Derived Mesenchymal Stromal/Stem Cells Are Induced by INF-γ Produced by Activated Lymphomonocytes…

2020

Human mesenchymal stromal/stem cells (MSCs), being immunoprivileged and having immunomodulatory ability, represent a promising tool to be applied in the field of regenerative medicine. Based on numerous in vitro evidences, the immunological effects of MSCs on immune cells could depend on different mechanisms as cell-to-cell contact and paracrine signals. Furthermore, recent studies have shown that the immunomodulatory activity of MSCs is initiated by activated immune cells; thus, their interaction represents a potential homeostatic mechanism by which MSCs regulate the immune response. MSCs also release exosomes able to give different effects, in a paracrine manner, by influencing inflammato…

0301 basic medicineProgrammed Cell Death 1 ReceptorCell CommunicationLymphocyte ActivationimmunomodulationB7-H1 AntigenMonocytes0302 clinical medicineImmunology and AllergyOriginal ResearchChemistryCell DifferentiationHealthy VolunteersI-kappa B KinaseCell biologymedicine.anatomical_structureprimed-hAMSCsMonocyte differentiationCytokinesStem celllcsh:Immunologic diseases. AllergyStromal cellT cellPrimary Cell CultureImmunologyregenerative medicineexosomesInterferon-gamma03 medical and health sciencesParacrine signallingImmune systeminterferon-γmedicineHumansImmunologic FactorsAmnionhuman amnion-derived mesenchymal stem cellsCell ProliferationImmunosuppression TherapyPDL-1Mesenchymal stem cellImmunityM2-like monocytesMesenchymal Stem CellsCoculture TechniquesMicrovesiclesMicroRNAs030104 developmental biologyLeukocytes Mononuclearlcsh:RC581-607Interferon Regulatory Factor-1030215 immunologyFrontiers in Immunology
researchProduct